Does the AJC cancer staging system predict prognosis in patients with locally advanced esophageal squamous cell carcinoma?
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Postchemoradiotherapy (post-CRT) pathologic stage classified according to American Joint Committee on Cancer, 7th edition staging (AJCC-7) predicted survival in locally advanced esophageal squamous cell carcinoma (ESCC) patients treated with preoperative paclitaxel and cisplatin-based CRT followed by esophagectomy.
This study evaluated the prognostic value of AJCC-7 staging in 140 patients from three phase II trials of preoperative CRT (twice weekly paclitaxel and cisplatin-based regimens and 40-Gy radiotherapy in 20 fractions) for locally advanced ESCC; median follow-up was 61.9 months.
For the entire cohort, median progression-free survival (PFS) and overall survival (OS) were 24.5 and 30.9 months, respectively.